Oxford Cannabinoid Technologies Holdings PLC - ESG Rating & Company Profile powered by AI
This webpage displays a zero-cost Environmental, Social and Governance assessment covering Oxford Cannabinoid Technologies Holdings PLC. Check the bottom of this page for potential risks for Oxford Cannabinoid Technologies Holdings PLC based on industry, geography and size. The Disclosure rating covers 17 UN Sustainable Development Goals including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'.
Oxford Cannabinoid Technologies Holdings PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.5; made up of an environmental score of 3.0, social score of 4.0 and governance score of 5.0.
6.5
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
389 | Synthetic Biologics Inc | 6.6 | High |
389 | WuXi Biologics (Cayman) Inc | 6.6 | High |
401 | Oxford Cannabinoid Technologies Holdings PLC | 6.5 | High |
402 | Capricor Therapeutics Inc | 6.4 | High |
402 | Alembic Pharmaceuticals Ltd | 6.4 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Oxford Cannabinoid Technologies Holdings PLC have an accelerator or VC vehicle to help deliver innovation?
Does Oxford Cannabinoid Technologies Holdings PLC disclose current and historical energy intensity?
Does Oxford Cannabinoid Technologies Holdings PLC report the average age of the workforce?
Does Oxford Cannabinoid Technologies Holdings PLC reference operational or capital allocation in relation to climate change?
Does Oxford Cannabinoid Technologies Holdings PLC disclose its ethnicity pay gap?
Does Oxford Cannabinoid Technologies Holdings PLC disclose cybersecurity risks?
Does Oxford Cannabinoid Technologies Holdings PLC offer flexible work?
Does Oxford Cannabinoid Technologies Holdings PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Oxford Cannabinoid Technologies Holdings PLC disclose the number of employees in R&D functions?
Does Oxford Cannabinoid Technologies Holdings PLC conduct supply chain audits?
Does Oxford Cannabinoid Technologies Holdings PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Oxford Cannabinoid Technologies Holdings PLC conduct 360 degree staff reviews?
Does Oxford Cannabinoid Technologies Holdings PLC disclose the individual responsible for D&I?
Does Oxford Cannabinoid Technologies Holdings PLC disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Oxford Cannabinoid Technologies Holdings PLC disclose current and / or historical scope 2 emissions?
Does Oxford Cannabinoid Technologies Holdings PLC disclose water use targets?
Does Oxford Cannabinoid Technologies Holdings PLC have careers partnerships with academic institutions?
Did Oxford Cannabinoid Technologies Holdings PLC have a product recall in the last two years?
Does Oxford Cannabinoid Technologies Holdings PLC disclose incidents of discrimination?
Does Oxford Cannabinoid Technologies Holdings PLC allow for Work Councils/Collective Agreements to be formed?
Has Oxford Cannabinoid Technologies Holdings PLC issued a profit warning in the past 24 months?
Does Oxford Cannabinoid Technologies Holdings PLC disclose parental leave metrics?
Does Oxford Cannabinoid Technologies Holdings PLC disclose climate scenario or pathway analysis?
Does Oxford Cannabinoid Technologies Holdings PLC disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Oxford Cannabinoid Technologies Holdings PLC disclose the pay ratio of women to men?
Does Oxford Cannabinoid Technologies Holdings PLC support suppliers with sustainability related research and development?
Does Oxford Cannabinoid Technologies Holdings PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Oxford Cannabinoid Technologies Holdings PLC reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Oxford Cannabinoid Technologies Holdings PLC involved in embryonic stem cell research?
Does Oxford Cannabinoid Technologies Holdings PLC disclose GHG and Air Emissions intensity?
Does Oxford Cannabinoid Technologies Holdings PLC disclose its waste policy?
Does Oxford Cannabinoid Technologies Holdings PLC report according to TCFD requirements?
Does Oxford Cannabinoid Technologies Holdings PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Oxford Cannabinoid Technologies Holdings PLC disclose energy use targets?
Does Oxford Cannabinoid Technologies Holdings PLC disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Oxford Cannabinoid Technologies Holdings PLC have a policy relating to cyber security?
Have a different question?
Potential Risks for Oxford Cannabinoid Technologies Holdings PLC
These potential risks are based on the size, segment and geographies of the company.
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.